Article PDF

About the Authors

Shaizadinova M.Z. – Senior nurse department №2 «Kadam» of NJSC "National Center for Children's Rehabilitation", Astana, Kazakhstan

Tleulinova R.R. – Director of Nursing of NJSC "National Center for Children's Rehabilitation", Astana, Kazakhstan

Dametova M.B. – №2 department nurse of NJSC "National Center for Children's Rehabilitation", Astana, Kazakhstan

Tanibergenova K.A. – №2 department nurse of NJSC "National Center for Children's Rehabilitation", Astana, Kazakhstan

Ospanova T.K. – №2 department nurse of NJSC "National Center for Children's Rehabilitation", Astana, Kazakhstan

Kadyrbekova K.B. – №2 department nurse of NJSC "National Center for Children's Rehabilitation", Astana, Kazakhstan

Аbstract

The article discusses modern approaches to the diagnosis, treatment and rehabilitation of patients with spinal muscular atrophy (SMA). This rare neurodegenerative disease caused by a mutation in the SMN1 gene leads to progressive muscle weakness and loss of motor function. The latest therapies, including antisense therapy, gene technologies, and assistive therapies, are analyzed. Special attention is paid to the role of nurses in patient care, their participation in condition monitoring, rehabilitation activities and education of patients' families. The key aspects of social adaptation, accessibility of educational programs and employment of patients with various types of diseases are considered.

Keywords

Spinal muscular atrophy, diagnosis, treatment, gene therapy, rehabilitation, nursing care, physiotherapy, social adaptation, inclusive education, medical support.

References

1. Зубкова В. С., Игнатовская И. И., Могробян М. Г. Редкие (орфанные) заболевания: социально-правовой аспект // Society and Security Insights. – 2023. – Т. 6. – № 1. – С. 135–144.
2. Darras B.T., De Vivo D.C., Swoboda K.J., et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls // New England Journal of Medicine. – 2021. – Vol. 385, No. 5. – P. 427–435.
3. Motyl A.A.L., Gillingwater T.H. Timing is everything: Clinical evidence supports presymptomatic treatment for spinal muscular atrophy // Cell Reports Medicine. – 2022. – Vol. 3, No. 8. – Article ID 100725.
4. Dangouloff T., Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives // Therapeutics and Clinical Risk Management. – 2019. – Vol. 15. – P. 1153–1161.
5. Cure SMA. State of SMA: 2024 Report. – [Электронный ресурс]. – URL: https://www.curesma.org (дата обращения: 10.05.2025).
6. Поленова В. С., Мусаева И. А., Кожахметова С. А. Международные отношения в сфере здравоохранения и медико-социальной сфере на примере Центра генных дерматозов Центральной Азии // ОРГЗДРАВ: Новости. Мнения. Обучение. Вестник ВШОУЗ. – 2024. – Т. 10. – № 4 (38). – С. 102–115.
7. Schroth M.K., Harrell J.M., Chang T., et al. Spinal muscular atrophy update in best practices: Treatment considerations // Neurology: Clinical Practice. – 2024. – Vol. 14, No. 4. – P. e200310.
8. Glascock J., Sampson J., Haidet-Phillips A., et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2 // Journal of Neuromuscular Diseases. – 2020. – Vol. 7, No. 2. – P. 97–100.
9. Полевиченко Е. В. Клинические рекомендации «Проксимальная спинальная мышечная атрофия 5q» (2020): знать и выполнять // Pallium: паллиативная и хосписная помощь. – 2020. – № 3. – С. 14–18.
10. Wang L., Zhang L. Circulating microRNAs as diagnostic biomarkers for motor neuron disease // Frontiers in Neuroscience. – 2020. – Vol. 14. – P. 354.
11. Mendell J.R., Al-Zaidy S.A., Shell R., et al. Single-dose gene-replacement therapy for spinal muscular atrophy // New England Journal of Medicine. – 2017. – Vol. 377, No. 18. – P. 1713–1722.
12. Finkel R.S., Chiriboga C.A., Vajsar J., et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study // The Lancet. – 2016. – Vol. 388, No. 10063. – P. 3017–3026.
13. Mercuri E., Finkel R.S., Muntoni F., et al. Diagnosis and management of spinal muscular atrophy: Part 1. Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care // Neuromuscular Disorders. – 2018. – Vol. 28, No. 2. – P. 103–115.
14. Verhaart I.E.C., Robertson A., Wilson I.J., et al. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review // Orphanet Journal of Rare Diseases. – 2017. – Vol. 12. – P. 124.
15. Bagga P., McKee D., Xu J., et al. Diving into progress: A review on current therapeutic advancements in spinal muscular atrophy // Frontiers in Neurology. – 2024. – Vol. 15. – Article ID 1368658.